BEST AVAILABLE COPY JAN 1 1 2002 JC10 Rec'd PCT/PTO CERTIFICATE OF MAILING nce is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231. Kimberly W. Zuehlke Typed or Printed Name Signature 10/29/01 Date BEAR008 **REQUEST FOR** Attorney Docket 1010 **CORRECTED FILING** Confirmation No. RECEIPT Peter Rowe First Named Inventor 09/700,696 Application Number June 12, 2001 Address to: Filing Date Commissioner for Patents 1646 Group Art Unit Washington, D.C. 20231 To Be Assigned **Examiner Name** NOVEL POLYPEPTIDE Title HORMONE PHOSPHATONIN

Sir:

1

A filing receipt for the above-identified patent application has been issued by the U.S. Patent and Trademark Office (copy attached) and has been found to contain the following error(s):

(1) The Continuing Data as claimed by Applicant should read --THIS

APPLICATION IS A 371 OF PCT/EP99/03403 05/18/1999, WHICH

APPLICATION CLAIMS PRIORITY TO 9819387.3 09/04/98 AND

WHICH APLICATION CLAIMS PRIORITY TO 9810681.8 05/18/1998--

If for any reason a fee is found to be necessary, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0815.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date

Karl Bozicev

Registration/No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200


Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\BEAR (formerly 8302)\008\Filing Receipt - Correction.doc

PERT AVAILABLE COPY





COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 www.uspto.gov

APPLICATION NUMBER

FILING DATE

GRP ART UNIT

FIL FEE REC'D ATTY.DOCKET.NO

DRAWINGS

CONFIRMATION NO. 1010

IND CLAIMS

09/700,696

06/12/2001

1646

819

Bozicevic Field & Francis

Suite 200

200 Middlefield Road Menio Park, CA 94025

Date Mailed: 10/15/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Pat nt Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

✓ Peter Stanley Rowe, London, UNITED KINGDOM;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/EP99/03403 05/18/1999

Foreign Applications

Missing WHICH APPLICATION CLAIMS PRIORITY TO 9819387.3 09/04/18

WHICH APPLICATION CLAIMS PEIDEITY TO Projected Publication Date: Not Applicable, filed prior to November 29,2000

9810681.8

05/18/98

Non-Publication Request: No

Early Publication Request: No

Title

Novel polypeptide hormone phosphatonin

Preliminary Class

435

** SMALL ENTITY **

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed und r 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).